Skip to main content
New product approved
for adults with major depressive disorder
     view press release

Turning patient needs into breakthrough discoveries.

Turning patient
needs into

about axsome

We are committed to developing products that meaningfully improve the lives of patients.

Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14.

learn about our pipeline

Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

learn about these CNS conditions & more

recent news

Auvelity™ is now approved!

Please see full Prescribing Information, including Boxed Warning, and the Medication Guide.

Axsome Therapeutics Completes U.S. Acquisition of Sunosi®

Please see full Prescribing Information and Medication Guide.

See all News

Working at Axsome

Join our team! Take a look at available positions.